https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Patient and health care professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: a cross sectional survey. https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54477 Tue 27 Feb 2024 14:56:37 AEDT ]]> Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5045 Sat 24 Mar 2018 07:45:38 AEDT ]]> Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46198 2 days 1 to 3, and etoposide 80 mg/m² days 1 to 3 (R-IE) every 21 days for 6 cycles plus 2 doses of rituximab. Revised international prognostic index 3–4 was seen in 53% and prior rituximab exposure in 60%. The complete and overall response rates were 55% and 76%, respectively. Median progression free survival (PFS) and overall survival were 23 and 24 months, respectively. Patients relapsing within 12 months of prior treatment had a median PFS of 2.5 months compared to 23 months for those relapsing beyond 12 months. Grade 3–4 thrombocytopenia and neutropenia occurred in one and eight patients, respectively. R-IE is an effective, well tolerated regimen in RR-DLBCL patients not fit for autoSCT.]]> Mon 14 Nov 2022 11:22:52 AEDT ]]>